3 Agents to Watch for Decompensated Cirrhosis from NASH : vi

HepaStem, BIV201, and Albutein are late-stage pipeline agents in development for NASH, focusing specifically on decompensated cirrhosis.

Related Keywords

United States , America , John Tchelingerian , Sravani Meka , Sandra Camprubi , Promethera Group , Acute On Chronic Liver Failure , End Stage Liver Disease , North America , Announces Initiation , Biovie Announces , Patient Enrollment , Ascites Phase , Encouraging Efficacy Data , Conduct Pivotal Registrational , Long Term Administration , Human Albumin , Subjects With Decompensated Cirrhosis , Study Record , Nash , Nonalcoholic Steatohepatitis , Pipeline , Hepastem , Albutein , Biv201 , Cirrhosis , Aclf , Liver , Ascites , Decompensated Cirrhosis ,